My focus is on translational immunology, committed to advancing fundamental biological insights into viable clinical therapies. My research program investigates the critical integration of Extracellular Vesicle (EV) biology, cancer immunology, and host-microbiome communication to elucidate mechanisms governing inflammation, immune suppression, and tumor progression.
Key research domains include the gut-lung axis and EV-mediated cross-kingdom signaling. We have successfully demonstrated that natural, plant-derived nanoparticles can functionally reprogram microbial communities and immune pathways, offering prophylactic potential against colitis, metabolic inflammation, and neuroimmune disorders. Furthermore, my work has revealed the essential role of oncogenic EVs in tumor immune modulation and lung cancer progression.
This research foundation is supported by over 30 peer-reviewed publications in high-impact journals (e.g., Nature Communications, Cell Host & Microbe, PNAS) and exceeding 3,000 citations.
The overarching objective is to harness nanovesicle-mediated communication for the development of highly precise, preventive immunotherapies targeting chronic inflammatory diseases and cancer.
My focus is on translational immunology, committed to advancing fundamental biological insights into viable clinical therapies. My research program investigates the critical integration of Extracellular Vesicle (EV) biology, cancer immunology, and host-microbiome communication to elucidate mechanisms governing inflammation, immune suppression, and tumor progression.
Key research domains include the gut-lung axis and EV-mediated cross-kingdom signaling. We have successfully demonstrated that natural, plant-derived nanoparticles can functionally reprogram microbial communities and immune pathways, offering prophylactic potential against colitis, metabolic inflammation, and neuroimmune disorders. Furthermore, my work has revealed the essential role of oncogenic EVs in tumor immune modulation and lung cancer progression.
This research foundation is supported by over 30 peer-reviewed publications in high-impact journals (e.g., Nature Communications, Cell Host & Microbe, PNAS) and exceeding 3,000 citations.
The overarching objective is to harness nanovesicle-mediated communication for the development of highly precise, preventive immunotherapies targeting chronic inflammatory diseases and cancer.